Sage Journals: Discover world-class research

Abstract

Use of adoptive T-cell therapy (ACT) is increasing; however, T-cell therapy can result in severe toxicity. Consequently, several suicide-gene strategies that allow selective destruction of the infused T cells have been described. We compared effectiveness of four such strategies in vitro in Epstein Barr virus (EBV)-cytotoxic T lymphocytes (CTLs). Herpes simplex virus thymidine kinase (HSV-TK), human inducible caspase 9 (iCasp9), mutant human thymidylate kinase (mTMPK), and human CD20 codon optimized genes were cloned in frame with 2A-truncated codon optimized CD34 (dCD34) in a retroviral vector. Codon-optimization considerably improved CD20 expression. EBV-CTLs could be efficiently transduced in all constructs, with transgene expression similar to the control vector containing dCD34 alone. Expression was maintained for prolonged cultures. Expression of the suicide genes was not associated with alterations in immunophenotype, proliferation, or function of CTLs. Activation of HSV-TK, iCasp9, and CD20 ultimately resulted in equally effective destruction of transduced T cells. However, while iCasp9 and CD20 effected immediate cell-death induction, HSV-TK-expressing T cells required 3 days of exposure to ganciclovir to reach full effect. mTMPK-transduced cells showed lower T-cell killing all time points. Our results suggest that the faster activity of iCasp9 might be advantageous in treating certain types of acutely life-threatening toxicity. Codon-optimized CD20 has potential as a suicide gene.

Marin and colleagues compare the effectiveness of four suicide-gene strategies in a model in vitro T-cell system. Herpes simplex virus thymidine kinase (HSV-TK), human inducible caspase 9 (iCasp9), mutant human thymidylate kinase (mTMPK), and human CD20 codon-optimized genes were cloned in frame with 2A-truncated codon optimized CD34 in a retroviral vector. Suicide-gene activation ultimately resulted in equally effective destruction of transduced T cells, with iCasp9 and CD20 displaying the most immediate induction of cell death.

Get full access to this article

View all access options for this article.

References

Alduaij

, Illidge

T.M.

2011. The future of anti-CD20 monoclonal antibodies: are we making progress? Blood, 117:2993–3001.

Bendle

G.M.

, Linnemann

, Hooijkaas

A.I.

et al. 2010. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med., 16:565–570.

Berger

, Flowers

M.E.

, Warren

E.H.

, Riddell

S.R.

2006. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood, 107:2294–2302.

Bonini

, Ferrari

, Verzeletti

et al. 1997. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science, 276:1719–24.

Bordignon

, Bonini

, Sarina

et al. 2012. Randomised Phase III trial of haploidentical HCT with or without an add-back strategy of HSV-TK donor lymphocytes in patients with high-risk acute leukaemia. J. Clin. Oncol., 30,suppl; abstr 6541).

Brentjens

, Yeh

, Bernal

et al. 2010. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther., 18:666–668.

Brentjens

R.J.

, Rivière

, Park

J.H.

et al. 2011. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 118:4817–28.

Clackson

, Yang

, Rozamus

L.W.

et al. 1998. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc. Natl. Acad. Sci. U.S.A., 95:10437–42.

Di Stasi

, Tey

S.K.

, Dotti

et al. 2011. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med., 365:1673–83.

10.

Donnelly

M.L.

, Hughes

L.E.

, Luke

et al. 2001. The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J. Gen. Virol., 82:1027–41.

11.

Heslop

H.E.

2010. Safer CARS. Mol. Ther., 18:661–662.

12.

Introna

, Barbui

A.M.

, Bambacioni

et al. 2000. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum. Gene Ther., 11:611–620.

13.

Iuliucci

J.D.

, Oliver

S.D.

, Morley

et al. 2001. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J. Clin. Pharmacol., 41:870–9.

14.

Lamers

C.H.

, Sleijfer

, Vulto

A.G.

et al. 2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol., 24:e20–2.

15.

Louis

C.U.

, Savoldo

, Dotti

et al. 2011. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood, 118:6050–6.

16.

Marin

, Pizzitola

, Agostoni

et al. 2010. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica., 95:2144–52.

17.

Morgan

R.A.

, Dudley

M.E.

, Wunderlich

J.R.

et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314:126–9.

18.

Morgan

R.A.

, Yang

J.C.

, Kitano

et al. 2010. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther., 18:843–851.

19.

Peggs

K.S.

, Verfuerth

, Pizzey

et al. 2003. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet, 362:13757.

20.

Porter

D.L.

, Levine

B.L.

, Kalos

et al. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med., 365:725–33.

21.

Pule

, Finney

, Lawson

2003. Artificial T-cell receptors. Cytotherapy., 5:211–26.

22.

Pule

M.A.

, Savoldo

, Myers

G.D.

et al. 2008. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med., 14:1264–70.

23.

Rettig

M.P.

, Ritchey

J.K.

, Meyerrose

T.E.

et al. 2003. Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease. Mol. Ther., 8:29–41.

24.

Riddell

S.R.

, Elliott

, Lewinsohn

D.A.

et al. 1996. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med., 2:216–23.

25.

Rivière

, Brose

, Mulligan

R.C.

1995. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. U.S.A., 92:6733–7.

26.

Rosenberg

S.A

. 2011. Cell transfer immunotherapy for metastatic solid cancer–what clinicians need to know. Nat. Rev. Clin. Oncol., 8:577–85.

27.

Savoldo

, Goss

, Liu

et al. 2001. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation, 72:1078–86.

28.

Sato

, Neschadim

, Konrad

et al. 2007. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol. Ther., 15:962–970.

29.

Schmid

, Uittenbogaart

C.H.

, Krall

W.J.

et al. 1992. Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. Cytometry., 13:204–208.

30.

Serafini

, Manganini

, Borleri

et al. 2004. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum. Gene Ther., 15,6:3–76.

31.

Stauss

H.J.

, Cesco-Gaspere

, Thomas

et al. 2007. Monoclonal T-cell receptors: new reagents for cancer therapy. Mol. Ther., 15:1744–50.

32.

Straathof

K.C.

, Pulè

M.A.

, Yotnda

et al. 2005. An inducible caspase 9 safety switch for T-cell therapy. Blood, 105:4247–4254.

33.

Turcotte

, Rosenberg

S.A.

2011. Immunotherapy for metastatic solid cancers. Adv. Surg., 45:341–60.

34.

Vogler

, Newrzela

, Hartmann

et al. 2010. An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol. Ther., 18:1330–1338.

35.

Weiner

G.J.

2010. Rituximab: mechanism of action. Semin Hematol., 47:115–23.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.33 MB

Comparison of Different Suicide-Gene Strategies for the Safety Improvement of Genetically Manipulated T Cells

Abstract

Get full access to this article

References

Supplementary Material